Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company’s vaccines and said it would cancel some contracts and stop funding mRNA drug development.

CSL Seqirus was one of the drugmakers the federal government listed this week as having its mRNA-related work cut. In an email to The N&O, a company spokesperson said its mRNA programs cited by HHS aren’t active and thus “this decision has no impact on our research.”

This was one in a continuing line of moves that have put Kennedy's vaccine skepticism into public policy, though scientists say the vaccines are safe.